Monday, May 01, 2023 CCTG IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer has been centrally activated. This study is being done to answer the following questions: Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment? If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker? As well as to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer. For more information please visit the CCTG IND243 members trial page.
